Addition of Hormone Therapy to Radiation Improves Survival in Intermediate-risk, Early-stage Prostate Cancer (03-9-2010)

Short-term hormone therapy delivered before and during moderate-dose radiation therapy improves survival and reduces risk of recurrence compared with radiation alone in men with intermediate-risk, early-stage prostate cancer. The results of this Phase... Continue Reading

Cystoscopy Alone Is the Most Cost-effective Way to Monitor for Recurrence of Bladder Cancer (03-9-2010)

The addition of a urine test to standard cystoscopy screening in order to monitor for bladder cancer recurrence unnecessarily increases the cost of monitoring as well as the risk for a false-positive result and does not improve tumor detection, according... Continue Reading

PCA3 Test May Help Guide Prostate Biopsy Decisions (03-8-2010)

The PCA3 urine test may help guide decisions about the need for repeat prostate biopsy in men with a negative initial biopsy but elevated PSA. These results were presented at the 2010 ASCO Genitourinary Cancer Symposium. Since the late 1980s, the primary... Continue Reading

Cabazitaxel Shows Promise in Advanced Prostate Cancer (03-5-2010)

Among men with metastatic, hormone refractory prostate cancer that has progressed after Taxotere® (docetaxel)-based chemotherapy, the investigational chemotherapy drug cabazitaxel may improve survival. The results of this Phase III clinical trial... Continue Reading

Laparoscopic Surgery and Open Surgery Produce Similar Complication Rates in Prostate Cancer (03-3-2010)

Laparoscopic prostatectomy and open radical prostatectomy produce similar outcomes and carry similar rates of postoperative complications, according to the results of a study published in an early online version of the Journal of Urology.1 Radical... Continue Reading

Abiraterone Produces Promising Results in Men with Hormone Refractory Prostate Cancer (03-2-2010)

According to the results of Phase II clinical trials, the investigational drug abiraterone appears to be active in men with hormone refractory prostate cancer (HRPC). These results were published in the Journal of Clinical Oncology. Current treatment... Continue Reading

Variability in Prostatectomy Results Not Entirely Explained by Experience of the Surgeon (02-24-2010)

Even among surgeons with a similar degree of experience, rates of prostate cancer recurrence after open radical prostatectomy can vary greatly. These results were published in the Journal of Urology. Prostatectomy for localized prostate cancer can... Continue Reading

Some Chinese Herbs May Increase Risk of Urinary Tract Cancer (02-18-2010)

The use of Chinese herbal products that contain aristolochic acid is associated with an increased risk of urinary tract cancer, according to the results of a study published in the Journal of the National Cancer Institute.[1] Previous research has... Continue Reading

Denosumab More Effective Than Zometa in Prostate Cancer Patients with Bone Metastases (02-10-2010)

Among men with bone metastases from prostate cancer, the investigational drug denosumab was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. Results from this Phase III clinical trial will... Continue Reading

Coffee May Reduce Risk of Lethal and Advanced Prostate Cancer (12-17-2009)

Men who drink coffee may have a reduced risk of developing lethal and advanced prostate cancer. These results were presented at the 2009 AACR Frontiers in Cancer Prevention Research conference. Prostate cancer is the most common cancer (other than skin... Continue Reading

Minimally Invasive Prostate Surgery May Have Pros and Cons (10-14-2009)

Laparoscopic radical prostatectomy, a less invasive surgical procedure that has gained in popularity in recent years, appears to result in shorter hospital stays, fewer blood transfusions, and fewer postoperative respiratory complications than open, retropubic... Continue Reading

Addition of Androgen Deprivation Therapy Improves Survival with Locally Advanced Prostate Cancer (10-8-2009)

In men with locally advanced prostate cancer, the addition of androgen deprivation therapy to radiation therapy improves overall and progression-free survival without substantially affecting cardiovascular mortality. These results, based on close to 10... Continue Reading